MUSTANG BIO, INC.
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
MBIO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US62818Q1040
- LEI:
- Country:
- United States of America
- Address:
- 95 SAWYER RD, 2453 WALTHAM
- Website:
- https://www.mustangbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapy into potential cures for difficult-to-treat diseases. The company's pipeline is centered on Chimeric Antigen Receptor (CAR) T cell therapies for hematologic cancers and solid tumors, as well as gene therapies for rare genetic disorders. Mustang Bio's strategy involves in-licensing promising next-generation therapies and advancing them through clinical development. A key component of its strategy is the development of in-house manufacturing capabilities to ensure the uniform and scalable production of its cell therapy candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all MUSTANG BIO, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MUSTANG BIO, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MUSTANG BIO, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
